-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Herpesviridae -X- _ O
reactivation -X- _ O
among -X- _ O
non-immunocompromised -X- _ O
critically -X- _ O
ill -X- _ O
patients -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
impaired -X- _ O
prognosis -X- _ O
, -X- _ O
especially -X- _ O
during -X- _ O
acute -X- _ O
respiratory -X- _ O
distress -X- _ O
syndrome -X- _ O
( -X- _ O
ARDS -X- _ O
) -X- _ O
. -X- _ O
However -X- _ O
, -X- _ O
little -X- _ O
is -X- _ O
known -X- _ O
about -X- _ O
herpes -X- _ O
simplex -X- _ O
virus -X- _ O
( -X- _ O
HSV -X- _ O
) -X- _ O
and -X- _ O
Cytomegalovirus -X- _ O
( -X- _ O
CMV -X- _ O
) -X- _ O
reactivation -X- _ O
occurring -X- _ O
in -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
severe -X- _ I-Patient
ARDS -X- _ I-Patient
under -X- _ O
veno-venous -X- _ B-Intervention
extracorporeal -X- _ I-Intervention
membrane -X- _ I-Intervention
oxygenation -X- _ I-Intervention
( -X- _ I-Intervention
ECMO -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
We -X- _ O
tried -X- _ O
to -X- _ O
determine -X- _ O
the -X- _ O
frequency -X- _ O
of -X- _ O
Herpesviridae -X- _ O
reactivation -X- _ O
and -X- _ O
its -X- _ O
impact -X- _ O
on -X- _ O
patients’ -X- _ O
prognosis -X- _ O
during -X- _ O
ECMO -X- _ B-Intervention
for -X- _ O
severe -X- _ O
ARDS. -X- _ O
RESULTS -X- _ O
: -X- _ O
During -X- _ B-Outcome
a -X- _ I-Outcome
5-year -X- _ I-Outcome
period -X- _ I-Outcome
, -X- _ I-Outcome
123 -X- _ I-Outcome
non-immunocompromised -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
severe -X- _ I-Outcome
ARDS -X- _ I-Outcome
requiring -X- _ I-Outcome
a -X- _ I-Outcome
veno-venous -X- _ I-Outcome
ECMO -X- _ I-Outcome
were -X- _ I-Outcome
included. -X- _ I-Outcome
Sixty-seven -X- _ I-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
54 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
experienced -X- _ I-Outcome
HSV -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
CMV -X- _ I-Outcome
reactivation -X- _ I-Outcome
during -X- _ I-Outcome
ECMO -X- _ I-Outcome
course -X- _ I-Outcome
( -X- _ I-Outcome
20 -X- _ I-Outcome
viral -X- _ I-Outcome
co-infection -X- _ I-Outcome
, -X- _ I-Outcome
40 -X- _ I-Outcome
HSV -X- _ I-Outcome
alone -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
7 -X- _ I-Outcome
CMV -X- _ I-Outcome
alone -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
HSV -X- _ I-Outcome
reactivation -X- _ I-Outcome
occurred -X- _ I-Outcome
earlier -X- _ I-Outcome
than -X- _ I-Outcome
CMV -X- _ I-Outcome
after -X- _ I-Outcome
the -X- _ I-Outcome
beginning -X- _ I-Outcome
of -X- _ I-Outcome
MV -X- _ I-Outcome
[ -X- _ I-Outcome
( -X- _ I-Outcome
6–15 -X- _ I-Outcome
) -X- _ I-Outcome
vs. -X- _ I-Outcome
19 -X- _ I-Outcome
( -X- _ I-Outcome
13–29 -X- _ I-Outcome
) -X- _ I-Outcome
days -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.01 -X- _ I-Outcome
] -X- _ I-Outcome
and -X- _ I-Outcome
after -X- _ I-Outcome
ECMO -X- _ I-Outcome
implementation -X- _ I-Outcome
[ -X- _ I-Outcome
( -X- _ I-Outcome
2–8 -X- _ I-Outcome
) -X- _ I-Outcome
vs. -X- _ I-Outcome
14 -X- _ I-Outcome
( -X- _ I-Outcome
10–20 -X- _ I-Outcome
) -X- _ I-Outcome
days -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.01 -X- _ I-Outcome
] -X- _ I-Outcome
. -X- _ I-Outcome
In -X- _ I-Outcome
univariate -X- _ I-Outcome
analysis -X- _ I-Outcome
, -X- _ I-Outcome
HSV -X- _ I-Outcome
/ -X- _ I-Outcome
CMV -X- _ I-Outcome
reactivation -X- _ I-Outcome
was -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
longer -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
mechanical -X- _ I-Outcome
ventilation -X- _ I-Outcome
[ -X- _ I-Outcome
( -X- _ I-Outcome
22–52.5 -X- _ I-Outcome
) -X- _ I-Outcome
vs. -X- _ I-Outcome
17.5 -X- _ I-Outcome
( -X- _ I-Outcome
9–28 -X- _ I-Outcome
) -X- _ I-Outcome
days -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.01 -X- _ I-Outcome
] -X- _ I-Outcome
, -X- _ I-Outcome
a -X- _ I-Outcome
longer -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
ECMO -X- _ I-Outcome
[ -X- _ I-Outcome
15 -X- _ I-Outcome
( -X- _ I-Outcome
10–22.5 -X- _ I-Outcome
) -X- _ I-Outcome
vs. -X- _ I-Outcome
9 -X- _ I-Outcome
( -X- _ I-Outcome
5–14 -X- _ I-Outcome
) -X- _ I-Outcome
days -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.01 -X- _ I-Outcome
] -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
prolonged -X- _ I-Outcome
ICU -X- _ I-Outcome
[ -X- _ I-Outcome
29 -X- _ I-Outcome
( -X- _ I-Outcome
19.5–47.5 -X- _ I-Outcome
) -X- _ I-Outcome
vs. -X- _ I-Outcome
16 -X- _ I-Outcome
( -X- _ I-Outcome
9–30 -X- _ I-Outcome
) -X- _ I-Outcome
days -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.01 -X- _ I-Outcome
] -X- _ I-Outcome
and -X- _ I-Outcome
hospital -X- _ I-Outcome
stay -X- _ I-Outcome
[ -X- _ I-Outcome
44 -X- _ I-Outcome
( -X- _ I-Outcome
29–63.5 -X- _ I-Outcome
) -X- _ I-Outcome
vs. -X- _ I-Outcome
24 -X- _ I-Outcome
( -X- _ I-Outcome
11–43 -X- _ I-Outcome
) -X- _ I-Outcome
days -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.01 -X- _ I-Outcome
] -X- _ I-Outcome
as -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
non-reactivated -X- _ I-Outcome
patients. -X- _ I-Outcome
However -X- _ I-Outcome
, -X- _ I-Outcome
in -X- _ I-Outcome
multivariate -X- _ I-Outcome
analysis -X- _ I-Outcome
, -X- _ I-Outcome
viral -X- _ I-Outcome
reactivation -X- _ I-Outcome
remained -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
prolonged -X- _ I-Outcome
MV -X- _ I-Outcome
only. -X- _ I-Outcome
When -X- _ I-Outcome
considered -X- _ I-Outcome
separately -X- _ I-Outcome
, -X- _ I-Outcome
both -X- _ I-Outcome
HSV -X- _ I-Outcome
and -X- _ I-Outcome
CMV -X- _ I-Outcome
reactivation -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
longer -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
MV -X- _ I-Outcome
as -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
non- -X- _ I-Outcome
reactivation -X- _ I-Outcome
patients -X- _ I-Outcome
[ -X- _ I-Outcome
29 -X- _ I-Outcome
( -X- _ I-Outcome
19.5–41 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
28 -X- _ I-Outcome
( -X- _ I-Outcome
20.5–37 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
, -X- _ I-Outcome
vs. -X- _ I-Outcome
17.5 -X- _ I-Outcome
( -X- _ I-Outcome
9–28 -X- _ I-Outcome
) -X- _ I-Outcome
days -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.05 -X- _ I-Outcome
] -X- _ I-Outcome
. -X- _ I-Outcome
Co-reactivation -X- _ I-Outcome
patients -X- _ I-Outcome
had -X- _ I-Outcome
a -X- _ I-Outcome
longer -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
MV -X- _ I-Outcome
[ -X- _ I-Outcome
58.5 -X- _ I-Outcome
( -X- _ I-Outcome
38–72.3 -X- _ I-Outcome
) -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.05 -X- _ I-Outcome
] -X- _ I-Outcome
and -X- _ I-Outcome
ICU -X- _ I-Outcome
stay -X- _ I-Outcome
[ -X- _ I-Outcome
51.5 -X- _ I-Outcome
( -X- _ I-Outcome
32.5–69 -X- _ I-Outcome
) -X- _ I-Outcome
vs. -X- _ I-Outcome
27.5 -X- _ I-Outcome
( -X- _ I-Outcome
17.75–35.5 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
29 -X- _ I-Outcome
( -X- _ I-Outcome
20–30.5 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
] -X- _ I-Outcome
as -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
HSV -X- _ I-Outcome
or -X- _ I-Outcome
CMV -X- _ I-Outcome
reactivation -X- _ I-Outcome
alone. -X- _ I-Outcome
In -X- _ I-Outcome
multivariate -X- _ I-Outcome
analysis -X- _ I-Outcome
, -X- _ I-Outcome
HSV -X- _ I-Outcome
reactivation -X- _ I-Outcome
remained -X- _ I-Outcome
independently -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
longer -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
MV -X- _ I-Outcome
and -X- _ I-Outcome
hospital -X- _ I-Outcome
length -X- _ I-Outcome
of -X- _ I-Outcome
stay. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Herpesviridae -X- _ B-Outcome
reactivation -X- _ I-Outcome
is -X- _ I-Outcome
frequent -X- _ I-Outcome
among -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
severe -X- _ I-Outcome
ARDS -X- _ I-Outcome
under -X- _ I-Outcome
veno-venous -X- _ I-Outcome
ECMO -X- _ I-Outcome
and -X- _ I-Outcome
is -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
longer -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
mechanical -X- _ I-Outcome
ventilation. -X- _ I-Outcome
The -X- _ O
direct -X- _ O
causative -X- _ O
link -X- _ O
between -X- _ O
HSV -X- _ O
and -X- _ O
CMV -X- _ O
reactivation -X- _ O
and -X- _ O
respiratory -X- _ O
function -X- _ O
worsening -X- _ O
under -X- _ O
ECMO -X- _ O
remains -X- _ O
to -X- _ O
be -X- _ O
confirmed -X- _ O
. -X- _ O

